Table 3.
Patients who visited hospital before admission or were admitted while under GC-related medication
| Primary AI | Central AI | Others | ALL | ||
|---|---|---|---|---|---|
| (N = 23) | (N = 136) | (N = 345) | (n = 504) | ||
| Visited before admission | Yes | 18 (78.3) | 108 (79.4) | 258 (74.8) | 384 (76.2) |
| Yes, within 90 days before | 15 (65.2) | 98 (72.1) | 224 (64.9) | 337 (66.9) | |
| Yes, within 14 days before | 11 (47.8) | 69 (50.7) | 161 (46.7) | 241 (47.8) | |
| Under GC-related medication | Oral GC | 5 (21.7) | 31 (22.8) | 68 (19.7) | 104 (20.6) |
| HC equivalent daily dosage (mg) | 15 (10–20) | 20 (10–22.5) | 20 (20–40) | 20 (10–40) | |
| Median [IQR] | |||||
| Intranasal GC | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Inhaled GC | 0 (0.0) | 1 (0.7) | 14 (4.1) | 15 (3.0) | |
| Drug that interacts with GC | 2 (8.7) | 3 (2.2) | 8 (2.3) | 13 (2.6) |
Abbreviations: IQR Interquartile range, HC hydrocortisone, GC glucocorticoid